Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

NCT07447570 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer
Radiotherapy
Anti-PD-1/CTLA-4 Antibody

Interventions

DRUG: Iparomlimab and Tuvonralimab injection
RADIATION: Hypofractionated Radiotherapy
DRUG: Chemotherapy

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University